BrainStorm Cell Therapeutics Announces In-Person Meeting with the FDA to Discuss Confirmatory Phase 3 Trial for NurOwn® in ALS

Meeting will take place on December 6; Company plans to seek Special Protocol Assessment
NEW YORK, Nov. 20, 2023 /PRNewswire/ --BrainStorm Cell Therapeutics Inc. , a leading developer of adult...

Related Keywords

California ,United States ,Chaim Lebovits ,Brainstorm Cell Therapeutics Inc ,National Ms Society ,Nasdaq ,Drug Administration ,European Medicines Agency ,California Institute For Regenerative Medicine ,Lifesci Advisors ,Brainstorm Cell Therapeutics Ltd ,Us Food Drug Administration ,Special Protocol Assessment ,Brainstorm Cell Therapeutics ,Chief Executive Officer ,Biologics License ,Floor Effect ,Storm Cell Therapeutics ,Orphan Drug ,California Institute ,Regenerative Medicine ,Sci Advisors ,Cell Therapeutics ,Markets ,